Emvision Medical Devices Ltd has released a press release.
EMVision Releases its FY25 Half Yearly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- US Ethics Approval Received for Pivotal Validation Trial
- EMVision Receives $2.12m R&D Tax Rebate
- Algorithms Deliver Excellent Results In EMView Study
- EMV Prepares for Trial Following Positive FDA Engagement
- Appendix 4E & Annual Report to 30 June 2024
Later from EMvision Medical Devices
- S&P DJI Announces March 2025 Quarterly Rebalance
- First Responder Scanner in Successful Aeromedical Testing
- Emu Pivotal Validation Trial Commences
- Activation of Second US Pivotal Trial Site, Mayo Clinic
- Enhanced Algorithm Performance From Continuous Innovation
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices